Abydos Pharma is a high-tech biomedical enterprise co-founded by overseas returnee scientists and senior professionals in pharmaceutical and chemical industries. The company proudly engages Professor K. Barry Sharpless, two-time Nobel laureate in Chemistry, as scientific advisor. It has successfully developed the synthetic process of Eribulin, reputed as the Mount Everest in small-molecule drug synthesis.
We keep focusing on the exploration of cutting-edge biomedical technologies and talent development. We strive to deliver integrated services including drug discovery, process development, analytical testing and formulation research, as well as sophisticated intermediates and active pharmaceutical ingredients that meet GMP requirements.
Fueled by the booming R&D of peptide drugs in recent years, we leverage our technological advantages to develop a new generation of soluble resin materials. This breakthrough drastically cuts synthesis costs, enhances product purity and efficiency, and sharply reduces organic solvent consumption. It achieves revolutionary progress in solid-phase peptide synthesis and boosts technological upgrading of the whole industry.
The company now has an R&D team of more than 200 members, equipped with independent R&D centers and production bases for active pharmaceutical ingredients and intermediates. Our full-range services cover compound screening, target validation, synthetic route design and optimization, analytical method development and verification, as well as pharmaceutical formulation research. We have built long-term strategic partnerships with prestigious pharmaceutical companies in Asia, North America, Europe and other regions, aiming to grow into one of the most trusted partners in global pharmaceutical research and development.
